Table of Contents
Leukemia Research and Treatment
Volume 2015 (2015), Article ID 476805, 9 pages
http://dx.doi.org/10.1155/2015/476805
Clinical Study

Characteristics of Adult T-Cell Leukemia/Lymphoma Patients with Long Survival: Prognostic Significance of Skin Lesions and Possible Beneficial Role of Valproic Acid

1Department of Biological Haematology/Martinique Registry of Haematological Malignancies, Pierre-Zobda Quitman Hospital, University Hospital of Martinique, 97200 Fort-de-France, Martinique
2Martinique Cancer Screening Center, 127 Route de Redoute, 97200 Fort-de-France, Martinique
3Clinical Research and Innovation Unit, Pierre-Zobda Quitman Hospital, University Hospital of Martinique, 97200 Fort-de-France, Martinique
4Department of Internal Medicine, Mangot-Vulcin Hospital, University Hospital of Martinique, 97232 Lamentin, Martinique
5Department of Internal Medicine, Pierre Zobda-Quitman Hospital, University Hospital of Martinique, 97200 Fort-de-France, Martinique

Received 12 March 2015; Revised 21 May 2015; Accepted 28 May 2015

Academic Editor: Christophe Nicot

Copyright © 2015 Plumelle Yves et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. J. Poiesz, F. W. Ruscetti, A. F. Gazdar, P. A. Bunn, J. D. Minna, and R. C. Gallo, “Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 77, no. 12, pp. 7415–7419, 1980. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Yoshida, I. Miyoshi, and Y. Hinuma, “Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 79, no. 6, pp. 2031–2035, 1982. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Gessain, F. Barin, J. C. Vernant et al., “Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis,” The Lancet, vol. 2, no. 8452, pp. 407–410, 1985. View at Google Scholar
  4. P. Rodgers-Johnson, D. C. Gajdusek, O. C. Morgan St, V. Zaninovic, P. S. Sarin, and D. S. Graham, “HTLV-I and HTLV-III antibodies and tropical spastic paraparesis,” The Lancet, vol. 2, no. 8466, pp. 1247–1248, 1985. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Osame, K. Usuku, S. Izumo et al., “HTLV-I associated myelopathy, a new clinical entity,” The Lancet, vol. 1, no. 8488, pp. 1031–1032, 1986. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Shimoyama, “Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87),” British Journal of Haematology, vol. 79, no. 3, pp. 428–437, 1991. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Kamada, M. Sakurai, K. Miyamoto et al., “Chromosome abnormalities in adult T-cell leukemia/lymphoma: a Karyotype Review Committee report,” Cancer Research, vol. 52, no. 6, pp. 1481–1493, 1992. View at Google Scholar · View at Scopus
  8. A. Lezin, N. Gillet, S. Olindo et al., “Histone deacetylase-mediated transcriptional activation reduces proviral loads in HTLV-1-associated myelopathy/tropical spastic paraparesis patients,” Blood, vol. 110, no. 10, pp. 3722–3728, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Olindo, G. Belrose, N. Gillet et al., “Safety of long-term treatment of HAM/TSP patients with valproic acid,” Blood, vol. 118, no. 24, pp. 6306–6309, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Belrose, A. Gross, S. Olindo et al., “Effects of valproate on Tax and HBZ expression in HTLV-1 and HAM/TSPT lymphocytes,” Blood, vol. 118, no. 9, pp. 2483–2491, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Achachi, A. Florins, N. Gillet et al., “Valproate activates bovine leukemia virus gene expression, triggers apoptosis, and induces leukemia/lymphoma regression in vivo,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 29, pp. 10309–10314, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. P. V. Afonso, M. Mekaouche, F. Mortreux et al., “Highly active antiretroviral treatment against STLV-1 infection combining reverse transcriptase and HDAC inhibitors,” Blood, vol. 116, no. 19, pp. 3802–3808, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. K. B. Hymes, “The role of histone deacetylase inhibitors in the treatment of patients with cutaneous T-cell lymphoma,” Clinical Lymphoma, Myeloma and Leukemia, vol. 10, no. 2, pp. 98–109, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Campàs-Moya, “Romidepsin for the treatment of cutaneous t-cell lymphoma,” Drugs of Today, vol. 45, no. 11, pp. 787–795, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Stathis, S. J. Hotte, E. X. Chen et al., “Phase 2 trial of oral vorinostat (suberoylanilide hydroxamid acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL),” Blood, vol. 109, no. 1, pp. 31–39, 2007. View at Publisher · View at Google Scholar
  16. S. Balasubramanian, J. Ramos, W. Luo, M. Sirisawad, E. Verner, and J. J. Buggy, “A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas,” Leukemia, vol. 22, no. 5, pp. 1026–1034, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. B. Zimmerman, A. Sargeant, K. Landes, S. A. Fernandez, C.-S. Chen, and M. D. Lairmore, “Efficacy of novel histone deacetylase inhibitor, AR42, in a mouse model of, human T-lymphotropic virus type 1 adult T cell lymphoma,” Leukemia Research, vol. 35, no. 11, pp. 1491–1497, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. J. Chen, M. Zhang, W. Ju, and T. A. Waldmann, “Effective treatment of a murine model of adult T-cell leukemia using depsipeptide and its combination with unmodified daclizumab directed toward CD25,” Blood, vol. 113, no. 6, pp. 1287–1293, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Hasegawa, Y. Yamada, K. Tsukasaki et al., “LBH589, a deacetylase inhibitor, induces apoptosis in adult T-cell leukemia/lymphoma cells via activation of a novel RAIDD-caspase-2 pathway,” Leukemia, vol. 25, no. 4, pp. 575–587, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Ageberg, K. Rydström, T. Relander, and K. Drott, “The histone deacetylase inhibitor valproic acid sensitizes diffuse large B-cell lymphoma cell lines to CHOP-induced cell death,” American Journal of Translational Research, vol. 5, no. 2, pp. 170–183, 2013. View at Google Scholar · View at Scopus
  21. C. Nishioka, T. Ikezoe, J. Yang et al., “Histone deacetylase inhibitors induce growth arrest and apoptosis of HTLV-1-infected T-cells via blockade of signaling by nuclear factor κB,” Leukemia Research, vol. 32, no. 2, pp. 287–296, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. T. Ichiyama, K. Okada, J. M. Lipton, T. Matsubara, T. Hayashi, and S. Furukawa, “Sodium valproate inhibits production of TNF-α and IL-6 and activation of NF-κB,” Brain Research, vol. 857, no. 1-2, pp. 246–251, 2000. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Bazarbachi, Y. Plumelle, J. C. Ramos et al., “Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes,” Journal of Clinical Oncology, vol. 28, no. 27, pp. 4177–4183, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Hodson, S. Crichton, S. Montoto et al., “Use of zidovudine and interferon alfa with chemotherapy improves survival in both acute and lymphoma subtypes of adult T-cell leukemia/lymphoma,” Journal of Clinical Oncology, vol. 29, no. 35, pp. 4696–4701, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. A. L. Bittencourt, H. S. Barbosa, A. Pimenta, and L. Farre, “A case of adult T-cell leukemia/lymphoma (ATL) with a survival of more than 13 years,” Acta Oncologica, vol. 47, no. 5, pp. 981–983, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. Y. Takasaki, M. Iwanaga, Y. Imaizumi et al., “Long-term study of indolent adult T-cell leukemia-lymphoma,” Blood, vol. 115, no. 22, pp. 4337–4343, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. Y. Plumelle, C. Gonin, A. Edouard et al., “Effect of Strongyloides stercoralis infection and eosinophilia on age at onset and prognosis of adult T-cell leukemia,” American Journal of Clinical Pathology, vol. 107, no. 1, pp. 81–87, 1997. View at Google Scholar · View at Scopus
  28. A. Utsunomiya, T. Ishida, A. Inagaki et al., “Clinical significance of a blood eosinophilia in adult T-cell leukemia/lymphoma: a blood eosinophilia is a significant unfavorable prognostic factor,” Leukemia Research, vol. 31, no. 7, pp. 915–920, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Amano, M. Kurokawa, K. Ogata, H. Itoh, H. Kataoka, and M. Setoyama, “New entity, definition and diagnostic criteria of cutaneous adult T-cell leukemia/lymphoma: human T-lymphotropic virus type 1 proviral DNA load can distinguish between cutaneous and smoldering types,” The Journal of Dermatology, vol. 35, no. 5, pp. 270–275, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. G. Kchour, M. Tarhini, M.-M. Kooshyar et al., “Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL),” Blood, vol. 113, no. 26, pp. 6528–6532, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. T. Ishida, T. Joh, N. Uike et al., “Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study,” Journal of Clinical Oncology, vol. 30, no. 8, pp. 837–842, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. R. A. H. Haynes II, E. Ware, C. Premanandan et al., “Cyclosporine-induced immune suppression alters establishment of HTLV-1 infection in a rabbit model,” Blood, vol. 115, no. 4, pp. 815–823, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. G. Gaudray, F. Gachon, J. Basbous, M. Biard-Piechaczyk, C. Devaux, and J.-M. Mesnard, “The complementary strand of the human T-cell leukemia virus type 1 RNA genome encodes a bZIP transcription factor that down-regulates viral transcription,” Journal of Virology, vol. 76, no. 24, pp. 12813–12822, 2002. View at Publisher · View at Google Scholar · View at Scopus
  34. T. Usui, K. Yanagihara, K. Tsukasaki et al., “Characteristic expression of HTLV-1 basic zipper factor (HBZ) transcripts in HTLV-1 provirus-positive cells,” Retrovirology, vol. 5, article 34, 11 pages, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. H. Lu, C. A. Pise-Masison, R. Linton et al., “Tax relieves transcriptional repression by promoting histone deacetylase 1 release from the human T-cell leukemia virus type 1 long terminal repeat,” Journal of Virology, vol. 78, no. 13, pp. 6735–6743, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. I. Lemasson, N. J. Polakowski, P. J. Laybourn, and J. K. Nyborg, “Transcription factor binding and histone modifications on the integrated proviral promoter in human T-cell leukemia virus-I-infected T-cells,” The Journal of Biological Chemistry, vol. 277, no. 51, pp. 49459–49465, 2002. View at Publisher · View at Google Scholar · View at Scopus
  37. I. Lemasson, N. J. Polakowski, P. J. Laybourn, and J. K. Nyborg, “Transcription regulatory complexes bind the human T-cell leukemia virus 5′ and 3′ long terminal repeats to control gene expression,” Molecular and Cellular Biology, vol. 24, no. 14, pp. 6117–6126, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. D. Sibon, L. Zane, M. E. Idrissi et al., “Mosaicism of HTLV-1 5′ LTR CpG methylation in the absence of malignancy,” Virus Research, vol. 178, no. 2, pp. 452–461, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. Y. Taniguchi, K. Nosaka, J.-I. Yasunaga et al., “Silencing of human T-cell leukemia virus type I gene transcription by epigenetic mechanisms,” Retrovirology, vol. 2, article 64, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. H. Akl, B. Badran, G. Dobirta et al., “Progressive loss of CD3 expression after HTLV-I infection results from chromatin remodeling affecting all the CD3 genes and persists despite early viral genes silencing,” Virology Journal, vol. 4, article 85, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. S. Kobayashi, Y. Tian, N. Ohno et al., “The CD3 versus CD7 plot in multicolor flow cytometry reflects progression of disease stage in patients infected with HTLV-1,” PLoS ONE, vol. 8, no. 1, Article ID e53728, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. Y. Tian, S. Kobayashi, N. Ohno et al., “Leukemic T cells are specifically enriched in a unique CD3dimCD7low subpopulation of CD4+ T cells in acute-type adult T-cell leukemia,” Cancer Science, vol. 102, no. 3, pp. 569–577, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. S. Nakahata, T. Ichikawa, P. Maneesaay et al., “Loss of NDRG2 expression activates PI3K-AKT signalling via PTEN phosphorylation in ATLL and other cancers,” Nature Communications, vol. 5, article 3393, 2014. View at Publisher · View at Google Scholar
  44. J.-I. Yasunaga, Y. Taniguchi, K. Nosaka et al., “Identification of aberrantly methylated genes in association with adult T-cell leukemia,” Cancer Research, vol. 64, no. 17, pp. 6002–6009, 2004. View at Publisher · View at Google Scholar · View at Scopus
  45. Y. Satou, J.-I. Yasunaga, M. Yoshida, and M. Matsuoka, “HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 3, pp. 720–725, 2006. View at Publisher · View at Google Scholar · View at Scopus
  46. C. Vernin, M. Thenoz, C. Pinatel et al., “HTLV-1 bZIP factor HBZ promotes cell proliferation and genetic instability by activating oncomiRs,” Cancer Research, vol. 74, no. 21, pp. 6082–6093, 2014. View at Publisher · View at Google Scholar
  47. T. Koiwa, A. Hamano-Usami, T. Ishida et al., “5′-Long terminal repeat-selective CpG methylation of latent human T-cell leukemia virus type 1 provirus in vitro and in vivo,” Journal of Virology, vol. 76, no. 18, pp. 9389–9397, 2002. View at Publisher · View at Google Scholar · View at Scopus
  48. M. Miyazaki, J.-I. Yasunaga, Y. Taniguchi, S. Tamiya, T. Nakahata, and M. Matsuoka, “Preferential selection of human T-cell leukemia virus type 1 provirus lacking the 5′ lone terminal repeat during oncogenesis,” Journal of Virology, vol. 81, no. 11, pp. 5714–5723, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. E. E. Cameron, K. E. Bachman, S. Myöhänen, J. G. Herman, and S. B. Baylin, “Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer,” Nature Genetics, vol. 21, no. 1, pp. 103–107, 1999. View at Publisher · View at Google Scholar · View at Scopus
  50. F. Mortreux, I. Leclercq, A.-S. Gabet et al., “Somatic mutation in human T-cell leukemia virus type 1 provirus and flanking cellular sequences during clonal expansion in vivo,” Journal of the National Cancer Institute, vol. 93, no. 5, pp. 367–377, 2001. View at Publisher · View at Google Scholar · View at Scopus
  51. H. Miyake, T. Suzuki, H. Hirai, and M. Yoshida, “Trans-activator tax of human T-cell leukemia virus type 1 enhances mutation frequency of the cellular genome,” Virology, vol. 253, no. 2, pp. 155–161, 1999. View at Publisher · View at Google Scholar · View at Scopus
  52. K. Tsukasaki, H. Tsushima, M. Yamamura et al., “Integration patterns of HTLV-1 provirus in relation to the clinical course of ATL; frequent clonal change at crisis from indolent disease,” Blood, vol. 89, no. 3, pp. 948–956, 1997. View at Google Scholar